· Global cell gene therapy CDMO gets underway with construction of an 11,200㎡ gene-modified cells and viral vectors production facility scheduled for completion by the end of 2025
· Synergizes cell therapy CDMO business based on core competencies of MEDIPOST and OmniaBio
MEDIPOST (CEO Wonil Oh) announced on the 7th (6th Canadian local time) that OmniaBio, the affiliate specializing in CDMO of cell and gene therapy, held a groundbreaking ceremony for the new cGMP production facility to expand the CDMO project.
Many industry insiders including the official of MEDIPOST, CEO Michael May from OmniaBio’s parent company CCRM, and CEO Trevor Dauphinee from Invest Ontario participated in this event.
The new cGMP production facility of OmniaBio will be constructed within the McMaster Innovation Park in Hamilton, Ontario, Canada and additional cell and gene therapy research will be conducted in the 7,500㎡ cGMP facilities scheduled for completion by the end of 2025. OmniaBio owns production facilities spanning 11,200㎡, including the existing 3,700㎡ cGMP facility in Toronto, and will grow as Canada’s most extensive cell and gene therapy CDMO company to provide unified services from the process development of cell gene therapy to early clinical trials, late clinical development, and commercialization.
OmniaBio, established by separating the cell and gene therapy CDMO division from the parent company CCRM, already has many clients in North America and conducts process development and consigned production of autologous and allogeneic cell therapy, iPSC, genetically modified cell therapy, stem cell therapy, and CAR T.
“OmniaBio will play a key role in creating a new medical paradigm by developing life-changing cell and gene therapy capable of changing the lives of people through the best facilities and professional personnel. We plan to expand the cell and gene therapy CDMO project beyond North America to the Asia Pacific region through a strategic cooperative relationship with MEDIPOST, the global leader of stem cell therapy,” CEO Mitchel Sivilotti of OmniaBio revealed at the event.
The official of MEDIPOST said, “OmniaBio possesses excellent competency regarding the process development and production of cell and gene therapy. We are confident that OmniaBio’s capabilities will combine with MEDIPOST’s know-how in the world’s first lifecycle development of stem cell therapy to create a synergistic effect in the global cell and gene therapy CDMO project.”
MEDIPOST invested CAD 90 million (KRW 90 billion) in OmniaBio through shares and convertible bonds in May to expand the CDMO project to North America, and currently owns a 39.6% stake of OmniaBio. MEDIPOST will be the largest shareholder of OmniaBio when convertible bonds are converted to common stock after 2027.
